Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
Authors:
Open Access
- 24 December 2025
- Vol. 15 (12) , e111980
Abstract
Introduction: There is an unmet clinical need for the development of novel treatment strategies to improve the outcome of children with frequent relapsing or steroid-dependent nephrotic syndrome. Obinutuzumab (OBI) is a second-generation anti-CD20 monoclonal antibody that has demonstrated its superiority to rituximab (RTX) in vitro and in vivo. Our assumption is that a single infusion of low-dose OBI will induce longer B-cell depletion, longer sustained remission and reduce the frequency of relapses and the use of oral immunosuppressors compared with a single infusion of RTX. Methods and analysis: We conduct a double-blind, multicentre, randomised, parallel group in a 1:1 ratio controlled trial. In the experimental group, patients receive 1 infusion of OBI (300 mg/1.73 m 2 ) and in the control group, the patients receive 1 infusion of RTX (375 mg/m 2 ). The primary outcome of the study is the occurrence of the first relapse within 12 months following the initiation of treatment and secondary outcomes include the time to first relapse, the total number of relapses during the 24-month follow-up period, and any adverse events such as infusion-related complications, infectious complications, hypogammaglobulinaemia and neutropenia. Ethics and dissemination: The study has been approved by the ethics committee (Comité de Protection des Personnes) of Sud Méditerrannée 2 and authorised by the French drug regulatory agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé). Results of the primary study and the secondary aims will be disseminated through peer-reviewed publications. Trial registration number: NCT05786768 . Eudract N°: 2022-003336-59.Keywords
Funding Information
- Programme Hospitalier de Recherche Clinique -PHRC 2020
This publication has 28 references indexed in Scilit:
- Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic SyndromeJAMA Pediatrics, 2018
- Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after paediatric kidney transplantation: a multicentre French cohortNephrology Dialysis Transplantation, 2017
- Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocolBMJ Open, 2017
- Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic?Pediatric Nephrology, 2016
- Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndromePediatric Nephrology, 2016
- B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic SyndromeJournal of the American Society of Nephrology, 2015
- Cyclophosphamide in steroid-dependent nephrotic syndromePediatric Nephrology, 2011
- Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experienceNephrology Dialysis Transplantation, 2005
- Change of the course of steroid-dependent nephrotic syndrome after rituximab therapyPediatric Nephrology, 2004
- PATHOGENESIS OF LIPOID NEPHROSIS: A DISORDER OF T-CELL FUNCTIONThe Lancet, 1974